{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-001706","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2022-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.594980+00:00","generated_at":"2026-06-27T20:51:53.981829+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alnylam promotes Dr. Akshay Vaishnaw to President; continues scientific leadership","bullets":["Dr. Vaishnaw appointed President effective Jan 1, 2022; previously President of R&D.","Receives $725,000 base salary, 60% target bonus, and $2M stock option grant vesting over 4 years.","Yvonne Greenstreet named CEO effective same date; Vaishnaw to lead sustainable innovation in R&D.","Vaishnaw has been at Alnylam since 2006; also serves on boards of Editas Medicine and Scholar Rock."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-001706","json":"https://secwatch.observer/filing/0001193125-22-001706.json","markdown":"https://secwatch.observer/filing/0001193125-22-001706.md","text":"https://secwatch.observer/filing/0001193125-22-001706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/d251998d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:51:53.981829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82ae28a208","claim":"Akshay K. Vaishnaw was appointed as President at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"a699bdc111","claim":"Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"As previously announced, Yvonne L. Greenstreet, MBChB, MBA, the Company’s former President and Chief Operating Officer, was appointed Chief Executive Officer effective January 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}